Curaleaf Holdings Past Earnings Performance
Past criteria checks 0/6
Curaleaf Holdings's earnings have been declining at an average annual rate of -30.4%, while the Pharmaceuticals industry saw earnings growing at 45.6% annually. Revenues have been growing at an average rate of 26.2% per year.
Key information
-30.4%
Earnings growth rate
-24.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 26.2% |
| Return on equity | -18.9% |
| Net Margin | -15.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why Curaleaf Holdings (TSE:CURA) Has A Meaningful Debt Burden
Dec 15
Investors Give Curaleaf Holdings, Inc. (TSE:CURA) Shares A 27% Hiding
Nov 09Curaleaf Holdings, Inc. (TSE:CURA) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless
Aug 13These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively
Jul 19Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%
Jun 14Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%
Jan 19Does Curaleaf Holdings (CSE:CURA) Have A Healthy Balance Sheet?
Dec 11Is Curaleaf Holdings (CSE:CURA) Using Too Much Debt?
Sep 08Curaleaf Holdings (CSE:CURA) Has Debt But No Earnings; Should You Worry?
May 28We Think Curaleaf Holdings (CSE:CURA) Is Taking Some Risk With Its Debt
Sep 05Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden
May 20Is Curaleaf Holdings (CSE:CURA) A Risky Investment?
Oct 26Revenue & Expenses Breakdown
How Curaleaf Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,357 | -206 | 445 | 0 |
| 30 Jun 24 | 1,360 | -221 | 436 | 0 |
| 31 Mar 24 | 1,353 | -237 | 434 | 0 |
| 31 Dec 23 | 1,347 | -230 | 435 | 0 |
| 30 Sep 23 | 1,342 | -346 | 451 | 0 |
| 30 Jun 23 | 1,334 | -318 | 455 | 0 |
| 31 Mar 23 | 1,312 | -268 | 452 | 0 |
| 31 Dec 22 | 1,275 | -258 | 448 | 0 |
| 30 Sep 22 | 1,244 | -157 | 440 | 0 |
| 30 Jun 22 | 1,234 | -202 | 453 | 0 |
| 31 Mar 22 | 1,232 | -223 | 449 | 0 |
| 31 Dec 21 | 1,196 | -206 | 426 | 0 |
| 30 Sep 21 | 1,118 | -164 | 398 | 0 |
| 30 Jun 21 | 984 | -90 | 356 | 0 |
| 31 Mar 21 | 790 | -57 | 293 | 0 |
| 31 Dec 20 | 627 | -57 | 258 | 0 |
| 30 Sep 20 | 472 | -52 | 207 | 0 |
| 30 Jun 20 | 351 | -50 | 160 | 0 |
| 31 Mar 20 | 282 | -72 | 142 | 0 |
| 31 Dec 19 | 221 | -67 | 115 | 0 |
| 30 Sep 19 | 178 | -57 | 104 | 0 |
| 30 Jun 19 | 137 | -84 | 91 | 0 |
| 31 Mar 19 | 103 | -64 | 75 | 0 |
| 31 Dec 18 | 77 | -56 | 60 | 0 |
| 30 Sep 18 | 51 | -40 | 42 | 0 |
| 30 Jun 18 | 36 | -6 | 30 | 0 |
| 31 Mar 18 | 25 | -3 | 22 | 0 |
| 31 Dec 17 | 19 | -3 | 18 | 0 |
| 31 Dec 16 | 4 | 0 | 5 | 0 |
Quality Earnings: CURA is currently unprofitable.
Growing Profit Margin: CURA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CURA is unprofitable, and losses have increased over the past 5 years at a rate of 30.4% per year.
Accelerating Growth: Unable to compare CURA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CURA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).
Return on Equity
High ROE: CURA has a negative Return on Equity (-18.91%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 11:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Curaleaf Holdings, Inc. is covered by 23 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Kenric Tyghe | ATB Capital Markets |
| Frederico Yokota Choucair Gomes | ATB Capital Markets |